Overview

Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety andefficacy of antroquinonol treatment of mild to moderate pneumonia due to COVID-19, as measured by the proportion of patients alive and free of respiratory failure.
Phase:
Phase 2
Details
Lead Sponsor:
Golden Biotechnology Corporation